9/14/2010

AstraZeneca obtained FDA approval for a 500-milligram dose of Faslodex, an injectable treatment for metastatic breast cancer in postmenopausal women who received anti-estrogen therapy. The strength replaces a previously approved 250-milligram dose.

Full Story:
Drug Store News

Related Summaries